Biotech | October 13, 2021
Roche’s 8-year safety data of Ocrevus shows reduced risk in multiple sclerosis patients
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
The Pune centre expands its presence beyond Bangalore and Hyderabad
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
It recommends using the vaccine to prevent the spread of the disease
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
Subscribe To Our Newsletter & Stay Updated
